Volume 129, Issue 7

Cover Figure: NPM-ALK—oncogene and therapeutic target. See the article by Werner et al.

WASHINGTON, February 16, 2017 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
Rea et al provide an important contribution to the evolving understanding of which patients with chronic myeloid leukemia (CML) are likely to achieve a treatment-free remission. Using rigorously defined criteria, they show that suboptimal response or resistance to tyrosine kinase inhibitor (TKI) treatment predicts poor response to discontinuation of TKI therapy in patients with chronic-phase CML.

A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER
Hunt et al elucidate the pathogenesis of a specific form of thrombotic microangiopathy that is induced by the intravenous abuse of extended-release oxymorphone tablets (Opana ER).

iNKT and memory B-cell alterations in HHV-8 multicentric Castleman disease
Human herpesvirus 8 (HHV-8), also known as Kaposi sarcoma herpesvirus, is a gammaherpesvirus that can infect a variety of cells, including B cells and antigen-presenting cells. Sbihi and colleagues provide the first evidence of invariant natural killer T-cell (iNKT) abnormalities in patients with HHV-8–associated multicentric Castleman disease.

Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK): the ultimate oncogene and therapeutic target
In a detailed review, Werner et al examine the oncogenic mechanisms induced by NPM-ALK. They describe the occurrence of ALK translocations in different malignancies, the various ALK partners and deregulated microRNAs, their functional consequences, and the potential of NPM-ALK as a therapeutic target.

Does ruxolitinib prolong the survival of patients with myelofibrosis?
This Evidence-Based Focused Review presents a thoughtful analysis of evidence regarding the effect of ruxolitinib on survival of patients with myelofibrosis.

How I treat atypical chronic myeloid leukemia
This How I Treat article describes the author’s personal approach to patients with atypical CML. The author presents selected clinical cases and describes the usual clinical presentation, cytological features, and cytogenetic and molecular abnormalities, and he offers algorithms for establishing a diagnosis and clinically relevant treatment options.

This week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.